CRISPR Shares Relatively Quiet As Traders Circulate Earlier Note From BTIG Suggesting 'Vertex's decision to exercise its options to in-license 3 added targets...could fuel speculation CRISPR will end up as Vertex takeover target.'
Benzinga Newsdesk